Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Pharvaris N.V. (PHVS)

Pharvaris N.V. (PHVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 606,552
  • Shares Outstanding, K 31,840
  • Annual Sales, $ 0 K
  • Annual Income, $ -109,180 K
  • 60-Month Beta -3.10
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.91
Trade PHVS with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.56
  • Number of Estimates 4
  • High Estimate -0.51
  • Low Estimate -0.61
  • Prior Year -0.69
  • Growth Rate Est. (year over year) +18.84%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.37 +23.94%
on 06/07/24
21.87 -12.89%
on 05/24/24
-1.53 (-7.43%)
since 05/21/24
3-Month
15.37 +23.94%
on 06/07/24
25.55 -25.44%
on 03/22/24
-5.95 (-23.80%)
since 03/21/24
52-Week
10.50 +81.43%
on 06/22/23
33.00 -42.27%
on 02/06/24
+7.62 (+66.67%)
since 06/21/23

Most Recent Stories

More News
Manufacturing, Housing Due Next Week in Canada

Monday U.S. Featured Earnings Legend Biotech Corporation (NASDAQ: LEGN) (Q1) EPS ...

CRDL.TO : 2.51 (-1.95%)
ORE.TO : 0.66 (-1.49%)
PBH.TO : 88.84 (-0.18%)
LEGN : 42.61 (+4.44%)
STNE : 11.72 (-1.92%)
PHVS : 19.05 (+5.60%)
BABA : 73.67 (-0.91%)
SONY : 80.53 (-0.37%)
CSCO : 47.29 (+1.22%)
TJX : 111.01 (+0.57%)
CPRT : 54.24 (+0.43%)
WMT : 67.91 (-0.15%)
Jobs Figures Roll out Next Week

Monday U.S. Economic Lookahead S&P U.S. manufacturing PMI (final) (Mar.) Construction ...

KNT.TO : 7.55 (-3.08%)
PVH : 114.43 (+2.23%)
SGML : 12.44 (+3.41%)
MVST : 0.4349 (-7.31%)
BRMI.TO : 0.71 (-5.33%)
PAYX : 125.96 (+0.70%)
PLAY : 40.99 (-3.33%)
AYI : 238.72 (-2.70%)
LEVI : 23.01 (-0.04%)
PHVS : 19.05 (+5.60%)
RPM : 111.39 (+0.44%)
LW : 84.85 (+2.86%)
Why Shares of Pharvaris N.V. Are Up Tuesday

Promising news from the Food and Drug Administration spurred the healthcare stock's rise.

PHVS : 19.05 (+5.60%)
Pharvaris to Participate in H.C. Wainwright 1st Annual Hereditary Angioedema (HAE) Conference

ZUG, Switzerland, July 14, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...

PHVS : 19.05 (+5.60%)
Pharvaris to Host Virtual Expert Perspectives on HAE: Unmet Needs and Therapeutic Options Webinar on July 13

ZUG, Switzerland, July 06, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...

PHVS : 19.05 (+5.60%)
Pharvaris Announces Annual Meeting of Shareholders

ZUG, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...

PHVS : 19.05 (+5.60%)
Pharvaris Participates in the Kinin 2022 Conference

Pharvaris’ tailored drug development approach to enable treatment of people living with all types of hereditary angioedema (HAE) presented at satellite...

PHVS : 19.05 (+5.60%)
Pharvaris Supports HAE Community by Participating in Company-wide Activities Challenge for May 16th hae day :-)

ZUG, Switzerland, May 16, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...

PHVS : 19.05 (+5.60%)
Pharvaris Appoints Joan Schmidt, J.D., as Chief Legal Officer

Pharvaris’ executive team further strengthened by Ms. Schmidt’s deep international experience and biopharmaceutical industry tenure ZUG, Switzerland, May ...

PHVS : 19.05 (+5.60%)
Pharvaris Reports First Quarter 2022 Financial Results and Provides Business Highlights

Target enrollment achieved in RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks; top-line data anticipated in 4Q22Enrollment...

PHVS : 19.05 (+5.60%)

Business Summary

Pharvaris N.V. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema and other bradykinin-B2-receptor-mediated...

See More

Key Turning Points

3rd Resistance Point 21.96
2nd Resistance Point 20.83
1st Resistance Point 19.94
Last Price 19.05
1st Support Level 17.92
2nd Support Level 16.79
3rd Support Level 15.90

See More

52-Week High 33.00
Fibonacci 61.8% 24.41
Fibonacci 50% 21.75
Fibonacci 38.2% 19.10
Last Price 19.05
52-Week Low 10.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar